Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4

Endocrinology

Volumn 152, Issue 8, 2011, Pages 3103-3112

  Kanoski, Scott E ^a   Fortin, Samantha M ^a   Arnold, Myrtha ^b   Grill, Harvey J ^a   Hayes, Matthew R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN (9-39); EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; PROTEIN INHIBITOR; SALCATONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEAFFERENTATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG MEGADOSE; FOOD INTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WEIGHT CHANGE;

ANIMALS; APPETITE DEPRESSANTS; BODY WEIGHT; BRAIN; CALCITONIN; EATING; GLUCAGON-LIKE PEPTIDE 1; MALE; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; VAGUS NERVE; VENOMS;

EID: 79960741385     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-0174     Document Type: Article

References (53)

1. Center for Disease Control and Prevention 2009 Overweight and obesity: data and statistics. Center for Disease Control and Prevention. www.cdc.gov/obesity/data/trends.html
2. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM 2007 The epidemiology of obesity. Gastroenterology 132:2087-2102 (Pubitemid 46693751)
3. Merchenthaler I, Lane M, Shughrue P 1999 Distribution of pre-proglucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261-280 (Pubitemid 28566834)
4. Mojsov S, Kopczynski MG, Habener JF 1990 Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265:8001-8008
5. Hayes MR, De Jonghe BC, Kanoski SE 2010 Role of the glucagon-like- peptide-1 receptor in the control of energy balance. Physiol Behav 100:503-510
6. Holst JJ 2007 The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439 (Pubitemid 350041474)
7. Holst JJ, Deacon CF 2005 Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48:612-615 (Pubitemid 40591213)
8. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME 2009 Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606-1616
9. Bradley DP, Kulstad R, Schoeller DA 2010 Exenatide and weight loss. Nutrition 26:243-249
10. Madsen AN, Hansen G, Paulsen SJ, Lykkegaard K, Tang-Christensen M, Hansen HS, Levin BE, Larsen PJ, Knudsen LB, Fosgerau K, Vrang N 2010 Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J Endocrinol 206:287-296
11. Thum T, Anker SD 2010 Liraglutide for weight loss in obese people. Lancet 375:551-552; author reply 552-553
12. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR 2005 The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044:127-131 (Pubitemid 40616060)
13. Rüttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W 2009 Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150:1174-1181
14. Williams DL, Baskin DG, Schwartz MW 2009 Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150:1680-1687
15. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D 2009 Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94:1843-1852
16. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M 2002 The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45:195-202 (Pubitemid 34208381)
17. Kastin AJ, Akerstrom V 2003 Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27:313-318
18. McClean P, Kung K, McCurtin R, Gault V, Holscher C, 2009 Novel GLP-1 analogues cross the blood brain barrier: a link between diabetes and Alzheimer's disease. The 39th Proc Annual Meeting of the Society for Neuroscience, Chicago, 2009
19. Norgren R, Smith GP 1994 A method for selective section of vagal afferent or efferent axons in the rat. Am J Physiol Regul Integr Comp Physiol 267:R1136-R1141
20. Ritter RC, Slusser PG, Stone S 1981 Glucoreceptors controlling feeding and blood glucose: location in the hindbrain. Science 213:451-452
21. Arnold M, Mura A, Langhans W, Geary N 2006 Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J Neurosci 26:11052-11060 (Pubitemid 44772195)
22. Moran TH, Baldessarini AR, Salorio CF, Lowery T, Schwartz GJ 1997 Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am J Physiol Regul Integr Comp Physiol 272:R1245-R1251
23. Smith GP, Jerome C, Norgren R 1985 Afferent axons in abdominal vagus mediate satiety effect of cholecystokinin in rats. Am J Physiol 249:R638-R641 (Pubitemid 16204020)
24. Walls EK, Phillips RJ, Wang FB, Holst MC, Powley TL 1995 Suppression of meal size by intestinal nutrients is eliminated by celiac vagal deafferentation. Am J Physiol Regul Integr Comp Physiol 269:R1410-R1419
25. Schepp W, Schmidtler J, Riedel T, Dehne K, Schusdziarra V, Holst JJ, Eng J, Raufman JP, Classen M 1994 Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2. Eur J Pharmacol 269:183-191
26. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M 1998 Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 101:1421-1430
27. Banks WA, During MJ, Niehoff ML 2004 Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther 309:469-475 (Pubitemid 38542596)
28. Knudsen LB 2010 Liraglutide: the therapeutic promise from animal models. Int J Clin Pract Suppl 64:4-11
29. Hayes MR, Skibicka KP, Grill HJ 2008 Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149:4059-4068
30. Scott KA, Moran TH 2007 The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 293:R983-R987 (Pubitemid 47358916)
31. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB 2007 Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56:8-15
32. Raun K, von Voss P, Knudsen LB 2007 Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 15:1710-1716 (Pubitemid 47264950)
33. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S 2007 Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30:1608-1610 (Pubitemid 46871185)
34. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM 2006 Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8:436-447 (Pubitemid 44349236)
35. Grill HJ 2006 Distributed neural control of energy balance: contributions from hindbrain and hypothalamus. Obesity (Silver Spring) 14(Suppl 5):216S-221S
36. Hayes MR, Bradley L, Grill HJ 2009 Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 150:2654-2659
37. McMahon LR, Wellman PJ 1997 Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. Pharmacol Biochem Behav 58:673-677 (Pubitemid 27438122)
38. McMahon LR, Wellman PJ 1998 PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol Regul Integr Comp Physiol 274:R23-R29
39. Kinzig KP, D'Alessio DA, Seeley RJ 2002 The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 22:10470-10476 (Pubitemid 35416883)
40. Becskei C, Grabler V, Edwards GL, Riediger T, Lutz TA 2007 Lesion of the lateral parabrachial nucleus attenuates the anorectic effect of peripheral amylin and CCK. Brain Res 1162:76-84 (Pubitemid 47088378)
41. Viltart O, Sartor DM, Verberne AJ 2006 Chemical stimulation of visceral afferents activates medullary neurones projecting to the central amygdala and periaqueductal grey. Brain Res Bull 71:51-59 (Pubitemid 44781151)
42. Hayes MR, Covasa M 2006 Gastric distension enhances CCK-induced Fos-like immunoreactivity in the dorsal hindbrain by activating 5-HT3 receptors. Brain Res 1088:120-130 (Pubitemid 43729418)
43. Vrang N, Hansen M, Larsen PJ, Tang-Christensen M 2007 Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Res 1149:118-126 (Pubitemid 46671416)
44. Chelikani PK, Haver AC, Reidelberger RD 2005 Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 288:R1695-R1706 (Pubitemid 40720720)
45. Baumgartner I, Pacheco-Lopez G, Ruttimann EB, Arnold M, Asarian L, Langhans W, Geary N, Hillebrand JJ 2010 Hepatic-portal vein infusions of GLP-1 reduce meal size and increase c-Fos expression in the NTS, AP, and CeA in rats. J Neuroendocrinol 22:557-563
46. Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ, Hellström PM 2009 Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 21:978-e78
47. Imeryüz N, Yeǧen BC, Bozkurt A, Coşkun T, Villanueva-Peñacarrillo ML, Ulusoy NB 1997 Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273:G920-G927
48. Baraboi ED, Smith P, Ferguson AV, Richard D 2010 Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the Glp-1 receptor agonist. Am J Physiol Regul Integr Comp Physiol 298:R1098-R1110
49. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP 1995 Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7:2294-2300
50. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL 2005 Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146:3748-3756 (Pubitemid 41175742)
51. Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM 2011 Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 19:121-127
52. Morley JE, Flood JF 1987 An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. Life Sci 41:2157-2165 (Pubitemid 18032328)
53. Grady EF, Böhm SK, Bunnett NW 1997 Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. Am J Physiol 273:G586-G601 (Pubitemid 27418778)